enGene Holdings Inc. Income Statement
ENGN / Health Care|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| SG&A Expense | $28.7M | $24.0M | $9.6M | $4.0M |
| R&D Expense | $94.5M | $38.3M | $16.5M | $15.5M |
| Operating Income | -$123.2M | -$62.3M | -$26.1M | -$19.4M |
| Interest Expense | - | - | $5.0M | $1.4M |
| Income Tax | $0 | -$19.0K | $17.0K | $22.0K |
| Net Income | -$117.3M | -$55.1M | -$99.9M | -$24.5M |
| EPS (Basic) | $2.29 | $1.46 | $151.22 | $44.30 |
| EPS (Diluted) | $2.29 | $1.46 | $151.22 | $44.30 |
| Shares Outstanding | 51.1M | 37.8M | 692.6K | 655.2K |